Chiquita Brooks-LaSure, CMS director (Caroline Brehman/CQ Roll Call via AP Images)

Ahead of lecanemab de­ci­sion, Alzheimer's groups pe­ti­tion CMS to re­verse cov­er­age pol­i­cy

Aduhelm’s suc­ces­sor is now weeks away from its PDU­FA date — and sev­er­al ad­vo­ca­cy groups are ar­gu­ing for the re­ver­sal of a con­tro­ver­sial CMS pol­i­cy.

The groups, in­clud­ing the Azheimer’s As­so­ci­a­tion and a num­ber of doc­tors and med­ical pro­fes­sion­als, are ad­vo­cat­ing for CMS to re­con­sid­er its Jan­u­ary an­nounce­ment that re­stricts the re­im­burse­ment of Aduhelm and oth­er an­ti-amy­loid mon­o­clon­al an­ti­bod­ies for Alzheimer’s dis­ease to pa­tients en­rolled in CMS-ap­proved, ran­dom­ized con­trolled tri­als.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters